Current therapies and challenges for the treatment of Staphylococcus aureus biofilm-related infections

Staphylococcus aureus is a major cause of nosocomial and community-acquired infections and contributes to significant increase in morbidity and mortality especially when associated with medical devices and in biofilm form. Biofilm structure provides a pathway for the enrichment of resistant and persistent phenotypes of S. aureus leading to relapse and recurrence of infection. Minimal diffusion of antibiotics inside biofilm structure leads to heterogeneity and distinct physiological activity. Additionally, horizontal gene transfer between cells in proximity adds to the challenges associated with eradication of biofilms. This narrative review focuses on biofilm-associated infections caused by S. aureus, the impact of environmental conditions on biofilm formation, interactions inside biofilm communities, and the clinical challenges that they present. Conclusively, potential solutions, novel treatment strategies, combination therapies, and reported alternatives are discussed.

Automated summary

Staphylococcus aureus is a significant cause of healthcare-associated and community-acquired infections, especially when associated with medical devices and in biofilm form. Biofilm structure allows for the enrichment of resistant and persistent phenotypes, leading to relapse and recurrence of infection. Minimal diffusion of antibiotics within biofilms leads to heterogeneity and distinct physiological activity. Horizontal gene transfer between cells in proximity adds to the challenges of eradicating biofilms. This review focuses on biofilm-associated infections caused by S. aureus, the impact of environmental conditions on biofilm formation, interactions within biofilm communities, and the clinical challenges they pose. Potential solutions, novel treatment strategies, combination therapies, and reported alternatives are also discussed.